14:25 , Jun 29, 2018 |  BC Week In Review  |  Financial News

NASH play Akero emerges from stealth with $65M

Investors in a $65 million series A round for Akero Therapeutics Inc. (Cambridge, Mass.) believe the company's newly acquired, Phase II-ready asset could best other therapies in efficacy to treat non-alcoholic steatohepatitis. New investors Atlas Venture,...
11:27 , Jun 25, 2018 |  BC Extra  |  Financial News

NASH play Akero emerges from stealth with $65M

Investors in a $65 million series A round for Akero Therapeutics Inc. (Cambridge, Mass.) believe the company's newly acquired, Phase II-ready asset could best other therapies in efficacy to treat non-alcoholic steatohepatitis. New investors Atlas Venture,...
16:41 , Jun 8, 2018 |  BC Week In Review  |  Financial News

Metacrine raises $65M series C

Metacrine Inc. (San Diego, Calif.) raised $65 million on June 6 in an untranched series C round led by Venrock Healthcare. New investors Franklin Templeton Investments, Deerfield Management, Arrowmark Partners, Invus, Lilly Asia Ventures and...
15:22 , Jun 8, 2018 |  BC Week In Review  |  Financial News

Enyo aims for Phase II HBV, NASH trials with €40M round

Enyo Pharma S.A. (Lyon, France) raised €40 million ($46.8 million) in a series B round led by OrbiMed Advisors. New investors Andera Partners (formerly Edmond de Rothschild Investment Partners) and Bpifrance Large Venture also participated,...
19:48 , Jun 6, 2018 |  BC Extra  |  Financial News

Metacrine raises $65M series C

Metacrine Inc. (San Diego, Calif.) raised $65 million in an untranched series C round led by Venrock Healthcare. New investors Franklin Templeton Investments, Deerfield Management, Arrowmark Partners, Invus, Lilly Asia Ventures and Vivo Capital also...
14:09 , Jun 4, 2018 |  BC Extra  |  Financial News

Enyo aims for Phase II HBV, NASH trials with €40M round

Enyo Pharma S.A. (Lyon, France) raised €40 million ($46.8 million) in a series B round led by OrbiMed Advisors. New investors Andera Partners (formerly Edmond de Rothschild Investment Partners) and Bpifrance Large Venture also participated,...
15:47 , May 31, 2018 |  BC Extra  |  Clinical News

Big gain for Madrigal on 36-week NASH readout

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) gained $157.18 (145%) to $265.61 on Thursday after it said MGL-3196 led to significant improvements vs. placebo in disease activity and disease resolution at week 36 in a Phase II trial...
17:58 , Apr 20, 2018 |  BC Week In Review  |  Clinical News

Intercept's Ocaliva improves fibrosis in subgroup of primary biliary cholangitis patients

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) reported data from a subgroup of 13 primary biliary cholangitis (PBC) patients with liver fibrosis or cirrhosis at baseline and who had paired liver biopsies in the Phase III POISE trial...
20:49 , Apr 6, 2018 |  BC Week In Review  |  Company News

Terns acquires NASH compounds from Eli Lilly

Terns Pharmaceuticals Inc. (San Mateo, Calif.) gained exclusive, worldwide rights to develop and commercialize three small molecule non-alcoholic steatohepatitis candidates from Eli Lilly and Co. (NYSE:LLY). The partners declined to disclose financial terms. Terns will initially...
17:10 , Apr 6, 2018 |  BC Week In Review  |  Financial News

Intercept raises $250M in two offerings

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) raised $250 million on April 5 from a pair of upsized offerings. The liver disease company raised $150 million through the sale of 2.3 million shares at $64 in a bumped-up follow-on...